Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease

Sjöwall, Christopher; Martinsson, Κjell; Cardell, Kristina; Ekstedt, Mattias; Kechagias, Stergios

doi:10.1016/j.trsl.2014.09.007

Cited by 29 publications

(31 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attempts were made to discover novel reliable non-invasive biomarkers of liver fibrosis, 37. Interestingly, high suPAR levels were correlated with fibrosis severity in two groups of patients with chronic liver disease: non-alcoholic fatty liver disease and chronic hepatitis C virus 37. Similar findings were more recently replicated in chronic hepatitis B 38…”

Section: Gastroenterologymentioning

confidence: 90%

“…Percutaneous liver biopsy remains the ‘gold standard’ to classify the stages of liver fibrosis. Attempts were made to discover novel reliable non-invasive biomarkers of liver fibrosis, 37. Interestingly, high suPAR levels were correlated with fibrosis severity in two groups of patients with chronic liver disease: non-alcoholic fatty liver disease and chronic hepatitis C virus 37.…”

Section: Gastroenterologymentioning

confidence: 99%

See 1 more Smart Citation

SuPAR, an emerging biomarker in kidney and inflammatory diseases

Hamie

Daoud

Nemer

et al. 2018

Postgraduate Medical Journal

View full text Add to dashboard Cite

Soluble urokinase plasminogen activator receptor (suPAR) is a circulating form of a physiological and pathophysiological important cell surface receptor, implicated in inflammation. Recent studies showed that suPAR is a promising biomarker, useful for diagnosis, assessment and prognosis of several diseases. This review summarises the majority of preliminary studies and analyses the significance and the clinical application of suPAR in various clinical conditions. SuPAR seems to have a significant value in the diagnosis as well as prognosis of many diseases; nonetheless, it merits large-scale studies to set cut-off values that help physicians in following up their patients and accordingly tailor their treatment plans.

show abstract

Section: Gastroenterologymentioning

confidence: 90%

Section: Gastroenterologymentioning

confidence: 99%

SuPAR, an emerging biomarker in kidney and inflammatory diseases

Hamie

Daoud

Nemer

et al. 2018

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Supar As a Clinical Marker Of Inflammation And Organ Damagementioning

confidence: 99%

“…Later, a substantial prognostic value of suPAR was demonstrated for infectious diseases such as HIV, tuberculosis, sepsis [5] and malaria [6][7][8][9]. Until today, suPAR has been evaluated as a biomarker of inflammation, organ damage and clinical outcome in numerous disorders including cardiovascular disease, hepatitis, renal disorders and rheumatic diseases [2,[10][11][12][13] but it was only recently studied in SLE [1,14], a disease where reliable biomarkers of disease activity and organ damage are highly warranted [15].…”

Section: Introductionmentioning

confidence: 99%

“…Further, it has been reported that it reflects overall immune activation and systemic inflammation [2]. suPAR has also emerged as a potential biomarker of fibrosis in chronic liver diseases of diverse etiology [10,11,[60][61][62].Recently, suPAR attracted significant attention in primary focal segmental glomerulosclerosis (FSGS). data from this pilot study revealed significantly higher suPAR levels among patients with moderately or highly elevated SDI after study inclusion, compared to patients without SDI increase (Figure 2).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Soluble urokinase plasminogen activator receptor—A valuable biomarker in systemic lupus erythematosus?

Enocsson¹,

Sjöwall²,

Wetterö³

2015

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

The expression of uPAR is mainly regulated by growth factors and pro-inflammatory cytokines like basic fibroblast growth factor, epidermal growth factor, tumor necrosis factor, interleukin ( suPAR as a clinical marker of inflammation and organ damagePlasma membrane expression of uPAR as well as the levels of circulating suPAR have been investigated in relation to a broad range of conditions and suPAR has been referred to as a "molecular crystal ball" due to its prognostic value in diseases like tuberculosis, HIV, sepsis and cancer [2,6,13,26,58,59]. Further, it has been reported that it reflects overall immune activation and systemic inflammation [2]. suPAR has also emerged as a potential biomarker of fibrosis in chronic liver diseases of diverse etiology [10,11,[60][61][62].Recently, suPAR attracted significant attention in primary focal segmental glomerulosclerosis (FSGS). data from this pilot study revealed significantly higher suPAR levels among patients with moderately or highly elevated SDI after study inclusion, compared to patients without SDI increase (Figure 2).Furthermore, there were higher death rates among patients in the two groups with SDI increase (Figure 2). However, it is well known that present organ damage predicts further organ damage [17,100], and thus, adjustment for SDI at baseline should be performed to reduce the risk of bias. A stepwise linear multiple regression analysis was therefore performed to evaluate the impact of suPAR on future SDI increase. After adjusting for age, sex and SDI at study inclusion, we found suPAR levels to have a significant impact on future SDI increase (p = 0.005, standardized β = 0.20) whereas SDI at study inclusion was excluded from the model. Since recent studies have revealed an inverse correlation between serum suPAR and glomerular filtration [67,68,96], we also included estimated glomerular filtration (eGFR) (calculated by the 4-variable Modification of Diet in Renal Disease StudyGroup formula [101]) in the analysis, but eGFR was not retained in the model. From these results, we suggest that suPAR can actually predict organ damage independent of present SDI score or eGFR, but that a prospective study examining the association between suPAR levels at the time of diagnosis with future SDI would be preferable.In line with these findings, elevated suPAR levels have previously been demonstrated to associate with the risk of developing cancer, cardiovascular disease and type 2 diabetes later in life in the general population [7]. Importantly, these associations were independent of CRP, which is known for its predictive value in cardiovascular disease [7,102].7 Potential roles of suPAR in SLE pathogenesisAssessment of circulating suPAR levels at the clinical laboratory could possibly become a future way to estimate organ damage in SLE, and suPAR would be an even more appealing biomarker candidate if the levels could be mechanistically linked to the disease. The pathogenesis of SLE is notoriously complex and not fully understood, but includes disturbances in t...

show abstract